Serotonin–glutamate receptor complex offers new drug target for psychosis
This article has no abstract so we have provided the first paragraph of the full text.
Recent advances in antipsychotic therapy have included the development of atypical neuroleptics that function by blocking neurotransmission by the serotonin (5-HT) receptor 2A (5-HT2A), and agents that function by interacting with the metabotropic glutamate receptor mGluR2 also seem to be effective in this setting. González-Maeso et al. have now found that 5-HT2A and mGluR2 physically and physiologically interact in the brain cortex to form a complex that integrates serotonin and glutamate signaling and might be involved in the development of the psychosis associated with schizophrenia.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Neuroscience A complex in psychosisNature News and Views (06 Mar 2008)
Research HighlightsNature Medicine News and Views (01 Mar 2008)
See all 4 matches for News And Views